Adjuvant treatment with the humanized monoclonal antibody trastuzumab in patients with early breast cancer;Adjuvante therapie mit trastuzumab bei mammakarzinompatientinnen

Deutsches Arzteblatt

Volumn 103, Issue 50, 2006, Pages

  Untch, Michael ^a,g   Jackisch, Christian ^b   Thomssen, Christoph ^c   Nitz, Ulrike ^d   Von Minckwitz, Gunter ^e   Kaufmann, Manfred ^f  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Klinikum Offenbach GmbH   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e German Breast Group   (Germany)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adjuvant therapy; Antibody; Breast cancer; Cancer therapy; Trastuzumab

Indexed keywords

CARBOPLATIN; DOCETAXEL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; EARLY CANCER; HORMONAL THERAPY; HUMAN; METASTASIS; REVIEW; RISK REDUCTION;

EID: 33846608343     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland Hrsg. in Zusammenarbeit mit dem Robert Koch Institut: Krebs in Deutschland. Häufigkeiten und Trends. Saarbrücken 2006, 52.
2. Goldhirsch A, Glick JH, Gelber RD et al.: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16: 1569-83.
3. Slamon DJ, Godolphin W, Jones LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
4. National Institute for Health and Clinical Excellence (NICE): Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. www.nice.org.uk
5. Romond EH, Perez EA, Bryant J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
6. Piccart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353; 1659-72.
7. Smith I, Procter M, Gelber RD et al.: Improved survival with trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. Lancet 2006 angenommen.
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.
9. Buzdar AU, Ibrahim NK, Francis D et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 1-10.
10. Tan-Chiu E, Yothers G, Romond E et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9.
11. Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO) Organkommission Mammakarzinom (2006): Adjuvante Therapie mit Trastuzumab. www.ago-online.org